Pfizer, Avon Foundation for Women reveal Avon-Pfizer Metastatic Breast Cancer Grants Program recipients

NewsGuard 100/100 Score

Today, Pfizer Inc. and the Avon Foundation for Women are proud to announce the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify. In total, 23 non-profit organizations will receive grants totaling $1 million in funding to support and educate more than 5,000 metastatic breast cancer patients, their caregivers, and their communities. The Avon-Pfizer Metastatic Breast Cancer Grants Program was created in June 2014 to support advocacy, academic and other nonprofit organizations that provide information and services to help people with metastatic breast cancer navigate the medical and emotional challenges associated with their disease.

"To date, the majority of public attention on and funding for breast cancer has centered on early-stage disease – such as screening strategies and survivorship – not on late-stage diagnosis. As a result, the Avon-Pfizer Metastatic Grants Program was established to address the gaps in support available to women and men living with metastatic disease, and to create new services for metastatic patients so they do not have to face this disease alone," said Marc Hurlbert, executive director of the Avon Foundation for Women Breast Cancer Crusade. "Our hope is that one day, all patients can access the unique care and support services they need, regardless of their ability to pay."

Metastatic breast cancer is the most advanced stage of breast cancer and occurs when cancer spreads beyond the breast to other parts of the body, including the bones, lungs, liver and brain. Nearly three in 10 women who have had early breast cancer will eventually develop metastatic disease. There are no cures currently available, and continuous treatment is needed to control the spread of the disease and its symptoms.

"Pfizer is proud to join the Avon Foundation in supporting these 23 important projects and the organizations driving them," said Maya Martinez-Davis, regional president, North America, Pfizer Oncology. "With the public breast cancer conversation focused primarily on early breast cancer, there is a need to foster greater understanding of metastatic disease and increased support for metastatic patients and their caregivers. Our hope is that the projects being funded by the Avon-Pfizer Metastatic Breast Cancer Grants Program will make a meaningful difference to the metastatic breast cancer community."

Each of the following 23 organizations will receive grants, ranging from $15,000 to $100,000, to:

  • Address gaps in services for the metastatic breast cancer community, including medical, psychological, nutritional, complementary and integrative services, support, financial, and legal support
  • Distribute resources and services available to vulnerable populations
  • Share educational resources with the public focusing on metastatic disease, palliative care, treatment options, clinical trials, access to holistic medication, and complementary medicine

Seven organizations will provide nationwide services, and the remaining grant-funded projects will provide local services in 16 states. Prominent national beneficiaries include: Living Beyond Breast Cancer, which has received a grant to focus on developing a metastatic breast cancer peer outreach and public relations program to connect patients to psychosocial services and information; BreastCancerTrials.org, which will focus on sharing clinical trial information with metastatic breast cancer patients; and Harborpath, Inc., which will focus on the development of a medication delivery web-based portal at no cost to low-income and uninsured patients at 23 institutions in a five-state area of the southeast.

The following organizations will receive grants:

  • Breastcancer.org (Narberth, Pa.)
  • Cancer Resource Center of the Desert (El Centro, Calif.)
  • Central Suffolk Hospital (New York)
  • Charlotte Maxwell Complementary Clinic (Oakland, Calif.)
  • City Of Hope (Duarte, Calif.)
  • Denver Health & Hospital Foundation (Denver, Colo.)
  • Gilda's Club of Northern New Jersey Inc. (Hackensack, N.J.)
  • God's Love We Deliver (New York)
  • H. Lee Moffitt Cancer Center and Research (Tampa, Fla.)
  • Harborpath, Inc. (Columbia, S.C.)
  • Living Beyond Breast Cancer (Haverford, Pa.)
  • Memorial Sloan Kettering Cancer Center (New York)
  • METAvivor Research and Support Inc. (Annapolis, Md.)
  • Methodist Healthcare Foundation (Memphis, Tenn.)
  • Patient Advocate Foundation Inc. (Hampton, Va.)
  • Quantum Leap Health Care Collaborative: BreastCancerTrials.org (San Francisco)
  • Sanford Medical Center Fargo (Fargo, N.D.)
  • SHARE Self-help for Women with Breast or Ovarian Cancer Inc. (New York)
  • The Breast Cancer Resource Centers Of Texas Inc. (Austin, Texas)
  • The Shanti Project Inc. (San Francisco)
  • Yale-New Haven Hospital (New Haven, Conn.)
  • You Can Thrive Foundation (New York)
  • Young Survival Coalition (New York)

SOURCE The Avon Foundation for Women

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery